Trials / Unknown
UnknownNCT03403556
High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes
A Randomized, Multicenter, Open, Parallel, Phase 4 Study to Compare the Efficacy and Safety Between High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in High ASCVD Risk Patients With Type 2 diabEtes (CREATE Study)
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Yuhan Corporation · Industry
- Sex
- All
- Age
- 40 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe compared to high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with type 2 diabetes
Detailed description
This study is to assess the efficacy and safety of Rosuvamibe® (rosuvastatin 10mg/ezetimibe 10mg) vs. rosuvastatin 20mg treated for 24 weeks in atherosclerotic cardiovascular disease risk (≥ 7.5%) patients with type 2 diabetes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvamibe | Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks |
| DRUG | Monorova | Rosuvastatin 20mg qd for 24 weeks |
Timeline
- Start date
- 2018-03-27
- Primary completion
- 2021-10-01
- Completion
- 2021-12-01
- First posted
- 2018-01-18
- Last updated
- 2020-12-14
Locations
6 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03403556. Inclusion in this directory is not an endorsement.